Willis Towers Watson
WTW
290.67
-1.31
-0.45%
Willis Towers Watson
US · WTW
#736 by market cap
Listed 1970
290.67
-1.31
-0.45%
Live - 5344 symbols - heartbeat 307s ago
· 2026-10-08 08:24
Pre-market
288.01
-0.92%
After-hours
290.67
0.00%
Overnight
288.50
-0.75%
- Market cap
- 27.00B
- P/E (TTM)i
- 18.00
- P/Bi
- 3.51
- EPSi
- 16.26
- Div yieldi
- 1.29%
- 52W posi
- 46%
Reader sentiment
Are you bullish or bearish on WTW?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 1.44, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -2.24% YoY
Margins
- Gross margin
- 42.06%
- Operating margin
- 23.25%
- Net margin
- 16.53%
Key ratios & quality
- Enterprise valuei
- 30.26B
- PEG ratioi
- 1.08
- Altman Z-Scorei
- 1.44
PEG uses trailing P/E against the 3-year net income growth rate (16.73%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 8.37B | 8.62B | 9.00B | -- | 8.87B | 9.48B | 9.93B | 9.71B |
| Gross profit | 3.44B | 3.46B | 3.75B | -- | 3.80B | 4.14B | 4.43B | 4.08B |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 1.07B | 993.00M | 1.42B | -- | 1.54B | 1.82B | 2.14B | 2.26B |
| Pretax profit | 1.05B | 1.01B | 2.69B | -- | 1.26B | 1.28B | 102.00M | 1.95B |
| Tax | 197.00M | 249.00M | 536.00M | -- | 194.00M | 215.00M | 192.00M | 318.00M |
| Net profit | 1.07B | 1.02B | 4.24B | -- | 1.02B | 1.06B | -88.00M | 1.61B |
| Basic EPS | 8 | 8 | 33 | -- | 9 | 10 | -1 | 16 |
| Diluted EPS | 8.02 | 7.65 | 32.78 | -- | 8.98 | 9.95 | -0.96 | 16.26 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 2.22B | 2.26B | 2.29B | 2.94B | 2.41B | 2.47B |
| Gross profit | 899.00M | 812.00M | 875.00M | 1.50B | 978.00M | 915.00M |
| Selling & admin expenses | -- | -- | -- | -- | -- | -- |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 432.00M | 370.00M | 420.00M | 1.04B | 489.00M | 425.00M |
| Pretax profit | 303.00M | 313.00M | 390.00M | 947.00M | 376.00M | 292.00M |
| Tax | 65.00M | -21.00M | 77.00M | 197.00M | 70.00M | 57.00M |
| Net profit | 239.00M | 332.00M | 306.00M | 736.00M | 303.00M | 231.00M |
| Basic EPS | 2 | 3 | 3 | 8 | 3 | 2 |
| Diluted EPS | 2.33 | 3.32 | 3.11 | 7.62 | 3.10 | 2.43 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 17.04B | 20.30B | 18.49B | -- | 15.84B | 13.43B | 15.11B | 16.87B |
| Cash & ST investments | 887.00M | 2.04B | 4.69B | -- | 1.26B | 1.42B | 1.89B | 3.17B |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 35.43B | 38.53B | 34.97B | -- | 31.77B | 29.09B | 27.68B | 29.53B |
| Total current liabilities | 16.07B | 19.33B | 14.72B | -- | 14.78B | 12.63B | 12.60B | 14.00B |
| Short-term debt | 480.00M | 1.12B | 763.00M | -- | 376.00M | 775.00M | 118.00M | 675.00M |
| Long-term debt | 5.30B | 4.66B | 3.97B | -- | 4.47B | 4.57B | 5.31B | 5.76B |
| Total liabilities | 25,057,000,000.00 | 27,599,000,000.00 | 21,662,000,000.00 | -- | 21,676,000,000.00 | 19,497,000,000.00 | 19,664,000,000.00 | 21,478,000,000.00 |
| Total equity | 10.37B | 10.93B | 13.31B | -- | 10.09B | 9.59B | 8.02B | 8.05B |
| Retained earnings | 1.79B | 2.43B | 4.65B | -- | 1.76B | 1.47B | 109.00M | -296.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 15.46B | 15.61B | 14.62B | 16.87B | 16.09B | 16.75B |
| Cash & ST investments | 1.51B | 1.99B | 1.93B | 3.17B | 1.86B | 1.66B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 28.06B | 28.48B | 27.44B | 29.53B | 29.64B | 30.56B |
| Total current liabilities | 13.38B | 13.87B | 13.24B | 14.00B | 13.55B | 15.25B |
| Short-term debt | 669.00M | 673.00M | 673.00M | 675.00M | 117.00M | 866.00M |
| Long-term debt | 4.76B | 4.76B | 4.76B | 5.76B | 6.30B | 5.78B |
| Total liabilities | 19,850,000,000.00 | 20,298,000,000.00 | 19,629,000,000.00 | 21,478,000,000.00 | 21,578,000,000.00 | 22,789,000,000.00 |
| Total equity | 8.21B | 8.18B | 7.81B | 8.05B | 8.06B | 7.77B |
| Retained earnings | 51.00M | -206.00M | -593.00M | -296.00M | -392.00M | -699.00M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 1.08B | 1.77B | 2.06B | -- | 812.00M | 1.35B | 1.51B | 1.78B |
| Depreciation & amortization | 729.00M | 770.00M | 650.00M | -- | 567.00M | 505.00M | 456.00M | 418.00M |
| Free cash flow | 776.00M | 1.49B | 1.86B | -- | 608.00M | 1.10B | 1.27B | 1.55B |
| Dividends paid | -329.00M | -346.00M | -374.00M | -- | -369.00M | -352.00M | -354.00M | -358.00M |
| Stock buybacks / issuance | -105.00M | 16.00M | -1.62B | -- | -3.52B | -1.00B | -901.00M | -1.65B |
| Ending cash balance | 4.18B | 6.30B | 7.69B | -- | 4.72B | 3.79B | 5.00B | 6.49B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -35.00M | 361.00M | 678.00M | 771.00M | -10.00M | 484.00M |
| Depreciation & amortization | 102.00M | 106.00M | 103.00M | 107.00M | 104.00M | 110.00M |
| Free cash flow | -86.00M | 303.00M | 621.00M | 708.00M | -65.00M | 425.00M |
| Dividends paid | -88.00M | -91.00M | -90.00M | -89.00M | -88.00M | -90.00M |
| Stock buybacks / issuance | -200.00M | -500.00M | -600.00M | -350.00M | -300.00M | -450.00M |
| Ending cash balance | 4.98B | 5.34B | 5.42B | 6.49B | 5.41B | 5.14B |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 10.39 | -- | -- | -- | 8.67 | 10.80 | -1.12 | 20.17 |
| ROA %i | 3.08 | 5.04 | -- | 4.60 | 3.02 | 3.47 | -0.35 | 5.61 |
| ROIC %i | 7.81 | -- | -- | -- | 6.92 | 8.08 | 0.75 | 12.68 |
| 5-year avg ROE %i | -- | 7.85 | -- | -- | 14.11 | 14.88 | 12.57 | 14.72 |
| EBIT margin %i | 17.21 | 15.66 | -- | 32.26 | 16.54 | 15.97 | 3.70 | 22.80 |
| FCF / sales %i | 8.59 | 6.20 | -- | 9.87 | 6.86 | 11.63 | 12.76 | 15.93 |
| Current ratioi | 1.06 | 1.05 | -- | 1.18 | 1.07 | 1.06 | 1.20 | 1.20 |
| Quick ratioi | 0.23 | 0.24 | -- | 0.80 | 0.26 | 0.33 | 0.43 | 0.45 |
| Debt / assetsi | 19.10 | 17.45 | -- | 106.13 | 17.25 | 20.42 | 21.43 | 23.38 |
| LT debt / equityi | 61.34 | 51.76 | -- | -- | 50.95 | 54.26 | 73.21 | 78.08 |
| Interest coveragei | 6.65 | 1.75 | -- | 13.76 | 7.05 | 6.44 | 1.40 | 8.51 |
| Revenue CAGR (3Y) %i | 6.66 | 1.78 | -- | -7.14 | 1.94 | 3.25 | 3.34 | 3.07 |
| Net income CAGR (3Y) %i | 20.89 | -22.85 | -- | -33.13 | -1.13 | 1.94 | -- | 16.73 |
| FCF CAGR (3Y) %i | 16.64 | -22.21 | -- | -21.66 | -7.81 | -9.50 | -12.01 | 36.49 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -0.60 | 1.57 | 27.79 | 20.17 | 20.70 | 19.83 |
| ROA %i | -0.18 | 0.47 | 7.75 | 5.61 | 5.78 | 5.30 |
| ROIC %i | 1.03 | 2.33 | 17.12 | 12.68 | 13.10 | 12.45 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 4.37 | 5.82 | 30.17 | 22.80 | 23.22 | 22.68 |
| FCF / sales %i | 12.40 | 12.02 | 14.08 | 15.93 | 15.83 | 16.72 |
| Current ratioi | 1.16 | 1.13 | 1.10 | 1.20 | 1.19 | 1.10 |
| Quick ratioi | 0.29 | 0.34 | 0.34 | 0.45 | 0.33 | 0.31 |
| Debt / assetsi | 21.12 | 20.84 | 21.54 | 23.38 | 23.30 | 23.24 |
| LT debt / equityi | 64.66 | 64.96 | 67.72 | 78.08 | 85.11 | 81.10 |
| Interest coveragei | 1.63 | 2.20 | 11.38 | 8.51 | 8.45 | 8.01 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Health, Wealth & Career (HWC) is the largest reported line at 51.50% of revenue, across 3 reported segments.
- Risk & Broking (R&B) follows at 47.20%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Health, Wealth & Career (HWC)51.50%
Risk & Broking (R&B)47.20%
Reimbursable expenses and other1.30%
Quote time 2026-10-08 08:24:54 · For reference only, not investment advice and not tailored to your situation.